Mechanistic examination of protein release from polymer nanofibers

M. Gandhi, R. Srikar, Alexander Yarin, C. M. Megaridis, R. A. Gemeinhart

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Therapeutic proteins have emerged as a significant class of pharmaceutical agents over the past several decades. The potency, rapid elimination, and systemic side effects have prompted the need of spatiotemporally controlled release for proteins maybe more than any other active therapeutic molecules. This work examines the release of two model protein compounds, bovine serum albumin (BSA) and an anti-integrin antibody (AI), from electrospun polyca-prolactone (PCL) nanofiber mats. The anti-integrin antibody was chosen as a model of antibody therapy; in particular, anti-integrin antibodies are a promising class of therapeutic molecules for cancer and angiogenic diseases. The release kinetics were studied experimentally and interpreted in the framework of a recently published theory of desorption-limited drug release from nondegrading-or very slowly degrading-fibers. The results are consistent with a protein release mechanism dominated by desorption from the polymer surface, while the polycaprolactone nanofibers are not degrading at an appreciable rate.

Original languageEnglish
Pages (from-to)641-647
Number of pages7
JournalMolecular Pharmaceutics
Volume6
Issue number2
DOIs
Publication statusPublished - 2009 Apr 6
Externally publishedYes

Fingerprint

Nanofibers
Polymers
Integrins
Anti-Idiotypic Antibodies
Proteins
Therapeutics
Bovine Serum Albumin
Antibodies
Pharmaceutical Preparations
Neoplasms

Keywords

  • Controlled release
  • Modeling
  • Nanofiber
  • Protein

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Molecular Medicine
  • Drug Discovery

Cite this

Gandhi, M., Srikar, R., Yarin, A., Megaridis, C. M., & Gemeinhart, R. A. (2009). Mechanistic examination of protein release from polymer nanofibers. Molecular Pharmaceutics, 6(2), 641-647. https://doi.org/10.1021/mp800160p

Mechanistic examination of protein release from polymer nanofibers. / Gandhi, M.; Srikar, R.; Yarin, Alexander; Megaridis, C. M.; Gemeinhart, R. A.

In: Molecular Pharmaceutics, Vol. 6, No. 2, 06.04.2009, p. 641-647.

Research output: Contribution to journalArticle

Gandhi, M, Srikar, R, Yarin, A, Megaridis, CM & Gemeinhart, RA 2009, 'Mechanistic examination of protein release from polymer nanofibers', Molecular Pharmaceutics, vol. 6, no. 2, pp. 641-647. https://doi.org/10.1021/mp800160p
Gandhi M, Srikar R, Yarin A, Megaridis CM, Gemeinhart RA. Mechanistic examination of protein release from polymer nanofibers. Molecular Pharmaceutics. 2009 Apr 6;6(2):641-647. https://doi.org/10.1021/mp800160p
Gandhi, M. ; Srikar, R. ; Yarin, Alexander ; Megaridis, C. M. ; Gemeinhart, R. A. / Mechanistic examination of protein release from polymer nanofibers. In: Molecular Pharmaceutics. 2009 ; Vol. 6, No. 2. pp. 641-647.
@article{1996ae495eda4f8894410e23432e1929,
title = "Mechanistic examination of protein release from polymer nanofibers",
abstract = "Therapeutic proteins have emerged as a significant class of pharmaceutical agents over the past several decades. The potency, rapid elimination, and systemic side effects have prompted the need of spatiotemporally controlled release for proteins maybe more than any other active therapeutic molecules. This work examines the release of two model protein compounds, bovine serum albumin (BSA) and an anti-integrin antibody (AI), from electrospun polyca-prolactone (PCL) nanofiber mats. The anti-integrin antibody was chosen as a model of antibody therapy; in particular, anti-integrin antibodies are a promising class of therapeutic molecules for cancer and angiogenic diseases. The release kinetics were studied experimentally and interpreted in the framework of a recently published theory of desorption-limited drug release from nondegrading-or very slowly degrading-fibers. The results are consistent with a protein release mechanism dominated by desorption from the polymer surface, while the polycaprolactone nanofibers are not degrading at an appreciable rate.",
keywords = "Controlled release, Modeling, Nanofiber, Protein",
author = "M. Gandhi and R. Srikar and Alexander Yarin and Megaridis, {C. M.} and Gemeinhart, {R. A.}",
year = "2009",
month = "4",
day = "6",
doi = "10.1021/mp800160p",
language = "English",
volume = "6",
pages = "641--647",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Mechanistic examination of protein release from polymer nanofibers

AU - Gandhi, M.

AU - Srikar, R.

AU - Yarin, Alexander

AU - Megaridis, C. M.

AU - Gemeinhart, R. A.

PY - 2009/4/6

Y1 - 2009/4/6

N2 - Therapeutic proteins have emerged as a significant class of pharmaceutical agents over the past several decades. The potency, rapid elimination, and systemic side effects have prompted the need of spatiotemporally controlled release for proteins maybe more than any other active therapeutic molecules. This work examines the release of two model protein compounds, bovine serum albumin (BSA) and an anti-integrin antibody (AI), from electrospun polyca-prolactone (PCL) nanofiber mats. The anti-integrin antibody was chosen as a model of antibody therapy; in particular, anti-integrin antibodies are a promising class of therapeutic molecules for cancer and angiogenic diseases. The release kinetics were studied experimentally and interpreted in the framework of a recently published theory of desorption-limited drug release from nondegrading-or very slowly degrading-fibers. The results are consistent with a protein release mechanism dominated by desorption from the polymer surface, while the polycaprolactone nanofibers are not degrading at an appreciable rate.

AB - Therapeutic proteins have emerged as a significant class of pharmaceutical agents over the past several decades. The potency, rapid elimination, and systemic side effects have prompted the need of spatiotemporally controlled release for proteins maybe more than any other active therapeutic molecules. This work examines the release of two model protein compounds, bovine serum albumin (BSA) and an anti-integrin antibody (AI), from electrospun polyca-prolactone (PCL) nanofiber mats. The anti-integrin antibody was chosen as a model of antibody therapy; in particular, anti-integrin antibodies are a promising class of therapeutic molecules for cancer and angiogenic diseases. The release kinetics were studied experimentally and interpreted in the framework of a recently published theory of desorption-limited drug release from nondegrading-or very slowly degrading-fibers. The results are consistent with a protein release mechanism dominated by desorption from the polymer surface, while the polycaprolactone nanofibers are not degrading at an appreciable rate.

KW - Controlled release

KW - Modeling

KW - Nanofiber

KW - Protein

UR - http://www.scopus.com/inward/record.url?scp=64649092924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64649092924&partnerID=8YFLogxK

U2 - 10.1021/mp800160p

DO - 10.1021/mp800160p

M3 - Article

VL - 6

SP - 641

EP - 647

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 2

ER -